Welcome to LookChem.com Sign In|Join Free

HENAN SUNLAKE ENTERPRISE CORPORATION

Free supplier Enterprise Certification

Free
supplier
8th
years
Home>>Products>>Cediranib

Product Certification&
Enterprise Certification

More Detail

HENAN SUNLAKE ENTERPRISE CORPORATION

Country: China (Mainland)

Business Type:Trading Company

Ms.summer

Tel: +86-371- 86259723

Mr.William

Tel: 17734809689

Ms.lisa

Tel: 17734809689

Ms.Tina

Tel: 86-371-86259723

Ms.Ann

Tel: 17734809689

Ms.Helen

Tel: 17734809689

Mobile: 17734809689

Tel: +86-371- 86259723

Fax: +86-371- 86259723

Province/state: HENAN

City: ZHENGZHOU

Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China

MaxCard:


qq Contact Suppliers

Cediranib

CAS NO.288383-20-0

  • FOB Price: USD: /Gram Get Latest Price
  • Min.Order: 100 Gram
  • Payment Terms: L/C,D/A,D/P,T/T,MoneyGram,Other
  • Available Specifications:

    1(10-100)Gram1(100-200)Gram

Contact Supplier

Product Details

Keywords

  • Recentin
  • HIGH purity by own lab 288383-20-0
  • AZD2171

Quick Details

  • ProName: Cediranib
  • CasNo: 288383-20-0
  • Molecular Formula: C25H27FN4O3
  • Appearance: white to brown low melting crystallin...
  • Application: 288383-20-0 Cediranib (AZD2171) inh...
  • DeliveryTime: Within 7 working days since received y...
  • PackAge: 1g;5g;10g;25g;50g;100g;500g;1KG;5KG,25...
  • Port: Any Chinese main ports
  • ProductionCapacity: 100 Kilogram/Month
  • Purity: 99%
  • Storage: 2-8, cold storage, to avoid light stor...
  • Transportation: BY SEA /BY AIR /BY COURIER
  • LimitNum: 100 Gram
  • Heavy metal: NULL
  • Grade: Industrial Grade,Food Grade,Pharma Gra...
  • Valid Period: 6 month
  • Application: Multipurpose intermediate
  • Certification: ISO/9001 Certificate

Superiority

 
Cediranib Basic information
Anticancer drugs
Product Name: Cediranib
Synonyms: Cediranib;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;Cadiranib (AZD2171);Cediranib(AZD2171);AZD2171;Recentin;Cadiranib;Cediranib R
CAS: 288383-20-0
MF: C25H27FN4O3
MW: 450.51
EINECS:  
Product Categories: APIs;Antineoplastic;Inhibitors
Mol File: 288383-20-0.mol
Cediranib Structure
 
Cediranib Chemical Properties
density  1.285
 
Safety Information
MSDS Information
 
 
Cediranib Usage And Synthesis
Anticancer drugs Cediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ / Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported. 
In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment.
The above information is edited by the chemicalbook of Tian Ye.
Usage Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively.

 

 

 

 

 

Service we provide:

 

1. Mixed container, we can mix different items in one container.

2. Quality control, before shipment, free sample for test. after shipment,  keep sample for 3 years

3. Prompt shipment with professional documents

4. Packing as your request, with photo before shipment

Details

  • Exhibition in shanghai

 

 

We have clients throughout the world:

Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.

 

 

 

 

 

 

 

Our Laboratoy

 

 

We have our own independent lab test center:

This makes sure that our technology support is reliable and authoritative.All of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.

 

 

 

 

 

Our factory

 

 

High quality with competitive price:

We are manufacturer and can provide high quality products with factory price

 

 

 

 

 

 

Package  & Shipment

 

 

Fast and safe delivery:

Parcels can be sent out within 24 hours after payment. Tracking number is available

Secure and discreet shipment. You have various choices of transportation methods

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hot Product